{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:02:38Z","timestamp":1791838958110,"version":"4.3.4"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"DOI":"10.1038\/s41573-026-01534-z","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:58:22Z","timestamp":1791359902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-generation immune cell engagers for B cell depletion in autoimmune diseases"],"prefix":"10.1038","author":[{"given":"Yakai","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-6945","authenticated-orcid":false,"given":"Bruno","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bitoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7993-7183","authenticated-orcid":false,"given":"Pierre","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5045-5255","authenticated-orcid":false,"given":"Maximilian F.","family":"Konig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-2360","authenticated-orcid":false,"given":"George C.","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-5895","authenticated-orcid":false,"given":"Marc","family":"Scherlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1534_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41573-025-01242-0","volume":"24","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger, M., Kolios, A. G. A., Kyttaris, V. C. & Tsokos, G. C. Advances in the treatment of systemic lupus erythematosus. Nat. Rev. Drug Discov. 24, 926\u2013944 https:\/\/doi.org\/10.1038\/s41573-025-01242-0 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1534_CR2","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","volume":"77","author":"B Terrier","year":"2018","unstructured":"Terrier, B. et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann. Rheum. Dis. 77, 1150\u20131156 https:\/\/doi.org\/10.1136\/annrheumdis-2017-212768 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson, A. et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing\u2013remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 21, 693\u2013703 https:\/\/doi.org\/10.1016\/S1474-4422(22)00209-5 (2022).","journal-title":"Lancet Neurol."},{"key":"1534_CR4","doi-asserted-by":"publisher","unstructured":"Scherlinger, M. et al. Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study. Ann. Rheum. Dis. 78, 1007\u20131010 https:\/\/doi.org\/10.1136\/annrheumdis-2018-214833 (2019).","DOI":"10.1136\/annrheumdis-2018-214833"},{"key":"1534_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215\u20131226 https:\/\/doi.org\/10.1002\/art.34359 (2012).","journal-title":"Arthritis Rheum."},{"key":"1534_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/m13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec, V. et al. Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann. Intern. Med. 160, 233\u2013242 https:\/\/doi.org\/10.7326\/m13-1085 (2014).","journal-title":"Ann. Intern. Med."},{"key":"1534_CR7","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur, C. et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann. Rheum. Dis. 84, 2065\u20132074 https:\/\/doi.org\/10.1016\/j.ard.2025.06.2120 (2025). This study compares the extent of lymph node B cell elimination achieved with obinutuzumab, blinatumomab, rituximab and CD19-directed CAR-T cell therapy in patients with SAIDs.","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR8","doi-asserted-by":"publisher","first-page":"22932","DOI":"10.1073\/pnas.2008523117","volume":"117","author":"A Ramesh","year":"2020","unstructured":"Ramesh, A. et al. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proc. Natl Acad. Sci. USA 117, 22932\u201322943 https:\/\/doi.org\/10.1073\/pnas.2008523117 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1534_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150999","volume":"6","author":"A Berti","year":"2021","unstructured":"Berti, A. et al. Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight 6, e150999 https:\/\/doi.org\/10.1172\/jci.insight.150999 (2021).","journal-title":"JCI Insight"},{"key":"1534_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/ar3220","volume":"13","author":"EA Szyszko","year":"2011","unstructured":"Szyszko, E. A. et al. Salivary glands of primary Sjogren\u2019s syndrome patients express factors vital for plasma cell survival. Arthritis Res. Ther. 13, R2 https:\/\/doi.org\/10.1186\/ar3220 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1534_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.6","volume":"7","author":"E Leah","year":"2011","unstructured":"Leah, E. Connective tissue diseases: long-lived plasma cells in Sjogren\u2019s syndrome \u2014 a salivary survival niche? Nat. Rev. Rheumatol. 7, 130 https:\/\/doi.org\/10.1038\/nrrheum.2011.6 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1534_CR12","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie, R. A. et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N. Engl. J. Med. 392, 1471\u20131483 https:\/\/doi.org\/10.1056\/NEJMoa2410965 (2025). This article reports the efficacy of anti-CD20 obinutuzumab in lupus nephritis.","journal-title":"N. Engl. J. Med."},{"key":"1534_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa2516150","volume":"395","author":"RA Furie","year":"2026","unstructured":"Furie, R. A. et al. Efficacy and safety of obinutuzumab in active systemic lupus erythematosus. N. Engl. J. Med. 395, 243\u2013254, https:\/\/doi.org\/10.1056\/NEJMoa2516150 (2026). This study provides further evidence supporting the efficacy of the anti-CD20 antibody obinutuzumab in patients with active SLE.","journal-title":"N. Engl. J. Med."},{"key":"1534_CR14","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak, R. J. et al. A phase 3 trial of inebilizumab in generalized myasthenia gravis. N. Engl. J. Med. 392, 2309\u20132320 https:\/\/doi.org\/10.1056\/NEJMoa2501561 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR15","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","volume":"7","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger, M. et al. CAR T-cell therapy in autoimmune diseases: where are we and where are we going. Lancet Rheumatol. 7, e434\u2013e447 https:\/\/doi.org\/10.1016\/S2665-9913(24)00377-1 (2025). This study provides a comprehensive review on the current and future strategies on CAR-T cell therapies in autoimmune diseases, including SLE.","journal-title":"Lancet Rheumatol."},{"key":"1534_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 https:\/\/doi.org\/10.1056\/NEJMoa2308917 (2024). This article reports the short-term and long-term efficacy and safety of CD19 CAR-T cell therapy in 15 patients with three distinct autoimmune diseases.","journal-title":"N. Engl. J. Med."},{"key":"1534_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41573-025-01349-4","volume":"25","author":"J Avouac","year":"2026","unstructured":"Avouac, J. et al. Roads and detours for CAR T cell therapy in autoimmune diseases. Nat. Rev. Drug Discov. 25, 290\u2013309 https:\/\/doi.org\/10.1038\/s41573-025-01349-4 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1534_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"Brinkmann, U. & Kontermann, R. E. The making of bispecific antibodies. MAbs 9, 182\u2013212 https:\/\/doi.org\/10.1080\/19420862.2016.1268307 (2017).","journal-title":"MAbs"},{"key":"1534_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway, J. B., Presta, L. G. & Carter, P. \u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617\u2013621 https:\/\/doi.org\/10.1093\/protein\/9.7.617 (1996).","journal-title":"Protein Eng."},{"key":"1534_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li, J. et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell 31, 383\u2013395 https:\/\/doi.org\/10.1016\/j.ccell.2017.02.001 (2017).","journal-title":"Cancer Cell"},{"key":"1534_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00446","volume":"10","author":"O Vafa","year":"2020","unstructured":"Vafa, O. & Trinklein, N. D. Perspective: designing T-cell engagers with better therapeutic windows. Front. Oncol. 10, 446 https:\/\/doi.org\/10.3389\/fonc.2020.00446 (2020).","journal-title":"Front. Oncol."},{"key":"1534_CR22","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood.2024026212","volume":"144","author":"H Lee","year":"2024","unstructured":"Lee, H. et al. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood 144, 2637\u20132651 https:\/\/doi.org\/10.1182\/blood.2024026212 (2024).","journal-title":"Blood"},{"key":"1534_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat5775","volume":"10","author":"D Slaga","year":"2018","unstructured":"Slaga, D. et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2\/CD3. Sci. Transl. Med. 10, eaat5775 https:\/\/doi.org\/10.1126\/scitranslmed.aat5775 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1534_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/17460441.2025.2522088","volume":"20","author":"O Abdelmotaleb","year":"2025","unstructured":"Abdelmotaleb, O., Schneider, A., Gassner, C., Marsch, S. & Klein, C. The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple? Expert Opin. Drug Discov. 20, 943\u2013949 https:\/\/doi.org\/10.1080\/17460441.2025.2522088 (2025).","journal-title":"Expert Opin. Drug Discov."},{"key":"1534_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein, C., Brinkmann, U., Reichert, J. M. & Kontermann, R. E. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug Discov. 23, 301\u2013319 https:\/\/doi.org\/10.1038\/s41573-024-00896-6 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1534_CR26","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"40","author":"A D\u2019Souza","year":"2022","unstructured":"D\u2019Souza, A. et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen\u00d7CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 40, 3576\u20133586 https:\/\/doi.org\/10.1200\/JCO.22.01504 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-193681","volume":"144","author":"S Gaballa","year":"2024","unstructured":"Gaballa, S. et al. Evaluation of AZD0486, a novel CD19\u00d7CD3 T-cell engager, in relapsed\/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: high complete responses seen in CAR-T-naive and CAR-T-exposed patients. Blood 144, 868 (2024).","journal-title":"Blood"},{"key":"1534_CR28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150757","volume":"138","author":"S Kumar","year":"2021","unstructured":"Kumar, S. et al. A phase 1 first-in-human study of Tnb-383B, a BCMA\u00d7CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. Blood 138, 900 (2021).","journal-title":"Blood"},{"key":"1534_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41577-025-01221-x","volume":"26","author":"Q Sun","year":"2026","unstructured":"Sun, Q. & Dong, C. Regulators of CD8+ T cell exhaustion. Nat. Rev. Immunol. 26, 129\u2013151 https:\/\/doi.org\/10.1038\/s41577-025-01221-x (2026).","journal-title":"Nat. Rev. Immunol."},{"key":"1534_CR30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179039","volume":"142","author":"D Sharon","year":"2023","unstructured":"Sharon, D. et al. Bivalent BCMA binding and low affinity CD3 T-cell engagement by Abbv-383 drives sustained activation with reduced T-cell exhaustion in preclinical models of multiple myeloma. Blood 142, 4666 https:\/\/doi.org\/10.1182\/blood-2023-179039 (2023).","journal-title":"Blood"},{"key":"1534_CR31","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-7326","volume":"85","author":"G Bian","year":"2025","unstructured":"Bian, G. et al. ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases. Cancer Res. 85, 7326 (2025).","journal-title":"Cancer Res."},{"key":"1534_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1158\/1535-7163.MCT-20-0061","volume":"20","author":"RJ Austin","year":"2021","unstructured":"Austin, R. J. et al. TriTACs, a novel class of T-cell-engaging protein constructs designed for the treatment of solid tumors. Mol. Cancer Ther. 20, 109\u2013120 https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0061 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1534_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008733","volume":"12","author":"RP O\u2019Connell","year":"2024","unstructured":"O\u2019Connell, R. P. et al. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma. J. Immunother. Cancer 12, e008733 https:\/\/doi.org\/10.1136\/jitc-2023-008733 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1534_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp, N. et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140, 1104\u20131118 https:\/\/doi.org\/10.1182\/blood.2022015956 (2022).","journal-title":"Blood"},{"key":"1534_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/imt-2023-0256","volume":"16","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3\/CD28 co-engagement. Immunotherapy 16, 143\u2013159 https:\/\/doi.org\/10.2217\/imt-2023-0256 (2024).","journal-title":"Immunotherapy"},{"key":"1534_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02329-8","volume":"11","author":"M Passariello","year":"2025","unstructured":"Passariello, M. et al. Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics. Cell Death Discov. 11, 58 https:\/\/doi.org\/10.1038\/s41420-025-02329-8 (2025).","journal-title":"Cell Death Discov."},{"key":"1534_CR37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129600","volume":"134","author":"P Horna","year":"2019","unstructured":"Horna, P., Nowakowski, G., Endell, J. & Boxhammer, R. Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies. Blood 134, 5345 (2019).","journal-title":"Blood"},{"key":"1534_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100\u2013107 https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/ar3909","volume":"14","author":"HE Mei","year":"2012","unstructured":"Mei, H. E., Schmidt, S. & Dorner, T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res. Ther. 14, S1 https:\/\/doi.org\/10.1186\/ar3909 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1534_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/cei\/uxae031","volume":"217","author":"K Shah","year":"2024","unstructured":"Shah, K. et al. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy. Clin. Exp. Immunol. 217, 15\u201330 https:\/\/doi.org\/10.1093\/cei\/uxae031 (2024).","journal-title":"Clin. Exp. Immunol."},{"key":"1534_CR41","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.ard.2025.06.510","volume":"84","author":"V Chindalore","year":"2025","unstructured":"Chindalore, V. et al. POS1160 A phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus. Ann. Rheum. Dis. 84, 1232\u20131233 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee, D. S. W., Rojas, O. L. & Gommerman, J. L. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat. Rev. Drug Discov. 20, 179\u2013199 https:\/\/doi.org\/10.1038\/s41573-020-00092-2 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1534_CR43","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci, L. et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat. Med. 30, 1593\u20131601 https:\/\/doi.org\/10.1038\/s41591-024-02964-1 (2024). This article reports the application of blinatumomab in patients with SAIDs.","journal-title":"Nat. Med."},{"key":"1534_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.06.464","volume":"84","author":"C Gebhardt","year":"2025","unstructured":"Gebhardt, C. et al. POS1113 Treatment of severe systemic sclerosis with blinatumomab, a bispecific anti-CD3\/CD19 T cell engager. Ann. Rheum. Dis. 84, 1197 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR45","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ard.2026.02.002","volume":"85","author":"M Scherlinger","year":"2026","unstructured":"Scherlinger, M. et al. Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series. Ann. Rheum. Dis. 85, 1172\u20131179 https:\/\/doi.org\/10.1016\/j.ard.2026.02.002 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR46","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2023022348","volume":"143","author":"SJ Schuster","year":"2024","unstructured":"Schuster, S. J. et al. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas. Blood 143, 822\u2013832 https:\/\/doi.org\/10.1182\/blood.2023022348 (2024).","journal-title":"Blood"},{"key":"1534_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ard.2025.05.394","volume":"84","author":"J Qi","year":"2025","unstructured":"Qi, J. et al. LB0007 CC312, a novel engineered CD19\/CD3\/CD28 tri-specific antibody, leads to rapid and deep B-cell depletion and has broad potential for development in autoimmune diseases. Ann. Rheum. Dis. 84, 319\u2013320 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-37415-z","volume":"16","author":"J Huang","year":"2026","unstructured":"Huang, J., Xu, Z., Zhang, X., Wang, X. & Zhang, L. Alterations in peripheral blood B cell subsets and their clinical significance in systemic lupus erythematosus. Sci. Rep. 16, 6293 https:\/\/doi.org\/10.1038\/s41598-026-37415-z (2026).","journal-title":"Sci. Rep."},{"key":"1534_CR49","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","volume":"7","author":"F Hiepe","year":"2011","unstructured":"Hiepe, F. et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat. Rev. Rheumatol. 7, 170\u2013178 https:\/\/doi.org\/10.1038\/nrrheum.2011.1 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1534_CR50","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","volume":"12","author":"F Hiepe","year":"2016","unstructured":"Hiepe, F. & Radbruch, A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat. Rev. Nephrol. 12, 232\u2013240 https:\/\/doi.org\/10.1038\/nrneph.2016.20 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"1534_CR51","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149\u20131155 https:\/\/doi.org\/10.1056\/NEJMoa2023325 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR52","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ajh.26628","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi, G. & Costa, L. J. Bispecific T-cell engagers for treatment of multiple myeloma. Am. J. Hematol. 98, S13\u2013S21 https:\/\/doi.org\/10.1002\/ajh.26628 (2023).","journal-title":"Am. J. Hematol."},{"key":"1534_CR53","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","volume":"84","author":"Z Hu","year":"2025","unstructured":"Hu, Z. et al. BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann. Rheum. Dis. 84, 1675\u20131683 https:\/\/doi.org\/10.1016\/j.ard.2025.06.2128 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR54","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. 83, 1304\u20131314 https:\/\/doi.org\/10.1136\/ard-2024-225785 (2024). This article reports the efficacy of CAR-T cell therapy dual-targeting BCMA and CD19 in the treatment of SLE.","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 https:\/\/doi.org\/10.1056\/NEJMoa2203478 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR56","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander, T., Kronke, J., Cheng, Q., Keller, U. & Kronke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med. 391, 864\u2013866 https:\/\/doi.org\/10.1056\/NEJMc2407150 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR57","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen, M. et al. BCMA-targeted T-cell-engager therapy for autoimmune disease. N. Engl. J. Med. 391, 867\u2013869 https:\/\/doi.org\/10.1056\/NEJMc2408786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR58","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","volume":"32","author":"C D\u00fcsing","year":"2026","unstructured":"D\u00fcsing, C. et al. Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases. Nat. Med. 32, 1530\u20131542 https:\/\/doi.org\/10.1038\/s41591-026-04238-4 (2026).","journal-title":"Nat. Med."},{"key":"1534_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.05.021","author":"FN Albach","year":"2026","unstructured":"Albach, F. N. et al. Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2026.05.021 (2026). This research describes the results of BCMA TCE teclistamab in patients across various SAIDs.","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.05.023","author":"E Siegert","year":"2026","unstructured":"Siegert, E. et al. Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis \u2014 a case series. Ann. Rheum. Dis. https:\/\/doi.org\/10.1016\/j.ard.2026.05.023 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR61","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1056\/nejmc2502297","volume":"392","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. BCMA-targeted T-cell engager for autoimmune hemolytic anemia after CD19 CAR T-cell therapy. N. Engl. J. Med. 392, 2282\u20132284 https:\/\/doi.org\/10.1056\/nejmc2502297 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR62","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","volume":"29","author":"D Roccatello","year":"2023","unstructured":"Roccatello, D. et al. Daratumumab monotherapy for refractory lupus nephritis. Nat. Med. 29, 2041\u20132047 https:\/\/doi.org\/10.1038\/s41591-023-02479-1 (2023).","journal-title":"Nat. Med."},{"key":"1534_CR63","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","volume":"25","author":"CL Zuch de Zafra","year":"2019","unstructured":"Zuch de Zafra, C. L. et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin. Cancer Res. 25, 3921\u20133933 https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2752 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1534_CR64","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232\u20132244 https:\/\/doi.org\/10.1056\/NEJMoa2204591 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01489-3","volume":"16","author":"J Zhao","year":"2023","unstructured":"Zhao, J., Ren, Q., Liu, X., Guo, X. & Song, Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. J. Hematol. Oncol. 16, 92 https:\/\/doi.org\/10.1186\/s13045-023-01489-3 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1534_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk6484","volume":"17","author":"S Tavakolpour","year":"2025","unstructured":"Tavakolpour, S. et al. Antigen-Fc fusion therapy reduces severity of a model of pemphigus vulgaris without systemic immunosuppression. Sci. Transl. Med. 17, eadk6484 https:\/\/doi.org\/10.1126\/scitranslmed.adk6484 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1534_CR67","volume":"76","author":"Y Xia","year":"2024","unstructured":"Xia, Y. Bispecific autoantigen-T cell engagers (BaiTE) to selectively target autoreactive B cells in antiphospholipid syndrome. Arthritis Rheumatol. 76, abstr. 0837 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1534_CR68","doi-asserted-by":"publisher","unstructured":"Liu, J. et al. Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.10.19.682634 (2025).","DOI":"10.1101\/2025.10.19.682634"},{"key":"1534_CR69","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.it.2022.09.007","volume":"43","author":"S Pinto","year":"2022","unstructured":"Pinto, S., Pahl, J., Schottelius, A., Carter, P. J. & Koch, J. Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends Immunol. 43, 932\u2013946 https:\/\/doi.org\/10.1016\/j.it.2022.09.007 (2022).","journal-title":"Trends Immunol."},{"key":"1534_CR70","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-3682-4","volume":"76","author":"J Liu","year":"2024","unstructured":"Liu, J. Precision targeting of autoreactive 9G4 B cells in systemic lupus erythematosus using engineered chimeric antigen receptor (CAR)- and chimeric T cell receptor (cTCR)-T cells. Arthritis Rheumatol. 76, abstr. 1751 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1534_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adr9382","volume":"18","author":"IJ Cohen","year":"2026","unstructured":"Cohen, I. J. et al. Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells. Sci. Transl. Med. 18, eadr9382 https:\/\/doi.org\/10.1126\/scitranslmed.adr9382 (2026).","journal-title":"Sci. Transl. Med."},{"key":"1534_CR72","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41586-022-05501-7","volume":"612","author":"X Yang","year":"2022","unstructured":"Yang, X. et al. Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides. Nature 612, 771\u2013777 https:\/\/doi.org\/10.1038\/s41586-022-05501-7 (2022).","journal-title":"Nature"},{"key":"1534_CR73","unstructured":"Glavaris, S. et al. TRBV9-targeted bispecific T cell-engaging antibodies to reset the autoreactive T cell compartment in spondyloarthritis and HLA-DQ8 celiac disease [abstract]. In ACR Convergence 2024 1707 (ACR, 2024)."},{"key":"1534_CR74","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41591-023-02613-z","volume":"29","author":"OV Britanova","year":"2023","unstructured":"Britanova, O. V. et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat. Med. 29, 2731\u20132736 https:\/\/doi.org\/10.1038\/s41591-023-02613-z (2023).","journal-title":"Nat. Med."},{"key":"1534_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1302354","volume":"14","author":"KEG Soto","year":"2023","unstructured":"Soto, K. E. G. et al. Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells. Front. Immunol. 14, 1302354 https:\/\/doi.org\/10.3389\/fimmu.2023.1302354 (2023).","journal-title":"Front. Immunol."},{"key":"1534_CR76","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv4937","volume":"11","author":"A Arina","year":"2025","unstructured":"Arina, A. et al. A universal chimeric antigen receptor (CAR)\u2013fragment antibody binder (FAB) split system for cancer immunotherapy. Sci. Adv. 11, eadv4937 https:\/\/doi.org\/10.1126\/sciadv.adv4937 (2025).","journal-title":"Sci. Adv."},{"key":"1534_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01938-8","volume":"23","author":"T Chen","year":"2024","unstructured":"Chen, T. et al. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments. Mol. Cancer 23, 53 https:\/\/doi.org\/10.1186\/s12943-024-01938-8 (2024).","journal-title":"Mol. Cancer"},{"key":"1534_CR78","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar, B. V., Connors, T. J. & Farber, D. L. Human T cell development, localization, and function throughout life. Immunity 48, 202\u2013213 https:\/\/doi.org\/10.1016\/j.immuni.2018.01.007 (2018).","journal-title":"Immunity"},{"key":"1534_CR79","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk, N. & Zweegman, S. T-cell-engaging bispecific antibodies in cancer. Lancet 402, 142\u2013158 https:\/\/doi.org\/10.1016\/S0140-6736(23)00521-4 (2023).","journal-title":"Lancet"},{"key":"1534_CR80","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41, 711\u2013725.e6 https:\/\/doi.org\/10.1016\/j.ccell.2023.02.008 (2023).","journal-title":"Cancer Cell"},{"key":"1534_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.454","volume":"84","author":"L Bucci","year":"2025","unstructured":"Bucci, L. et al. POS0057 Effects of T cell engagers treatment on B and T cells in autoimmune disease. Ann. Rheum. Dis. 84, 366 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR82","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/0008-5472.CAN-16-3431","volume":"77","author":"CH Chang","year":"2017","unstructured":"Chang, C. H. et al. Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells. Cancer Res. 77, 5384\u20135394 https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3431 (2017).","journal-title":"Cancer Res."},{"key":"1534_CR83","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","volume":"132","author":"M Herrmann","year":"2018","unstructured":"Herrmann, M. et al. Bifunctional PD-1 \u00d7 \u03b1CD3 \u00d7 \u03b1CD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood 132, 2484\u20132494 https:\/\/doi.org\/10.1182\/blood-2018-05-849802 (2018).","journal-title":"Blood"},{"key":"1534_CR84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","volume":"80","author":"M Kostine","year":"2021","unstructured":"Kostine, M. et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann. Rheum. Dis. 80, 36\u201348 https:\/\/doi.org\/10.1136\/annrheumdis-2020-217139 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw7888","volume":"12","author":"D Skokos","year":"2020","unstructured":"Skokos, D. et al. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci. Transl. Med. 12, eaaw7888 https:\/\/doi.org\/10.1126\/scitranslmed.aaw7888 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1534_CR86","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5989","volume":"11","author":"C Claus","year":"2019","unstructured":"Claus, C. et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci. Transl. Med. 11, eaav5989 https:\/\/doi.org\/10.1126\/scitranslmed.aav5989 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1534_CR87","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2531223","volume":"17","author":"C Bergamaschi","year":"2025","unstructured":"Bergamaschi, C. et al. Innovative strategies for T cell engagers for cancer immunotherapy. MAbs 17, 2531223 https:\/\/doi.org\/10.1080\/19420862.2025.2531223 (2025).","journal-title":"MAbs"},{"key":"1534_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101161","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch, M. et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep. Med. 4, 101161 https:\/\/doi.org\/10.1016\/j.xcrm.2023.101161 (2023).","journal-title":"Cell Rep. Med."},{"key":"1534_CR89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198745","volume":"144","author":"R Lawrence","year":"2024","unstructured":"Lawrence, R. et al. Pre-clinical evaluation of AZD5492, a novel CD8-guided T cell engager, for B-non Hodgkin lymphoma indications. Blood 144, 959 (2024).","journal-title":"Blood"},{"key":"1534_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01653-8","volume":"8","author":"Y Hu","year":"2023","unstructured":"Hu, Y. et al. \u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy. Signal Transduct. Target. Ther. 8, 434 https:\/\/doi.org\/10.1038\/s41392-023-01653-8 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1534_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007955","volume":"11","author":"GP Costa","year":"2023","unstructured":"Costa, G. P., Mensurado, S. & Silva-Santos, B. Therapeutic avenues for \u03b3\u03b4 T cells in cancer. J. Immunother. Cancer 11, e007955 https:\/\/doi.org\/10.1136\/jitc-2023-007955 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1534_CR92","doi-asserted-by":"publisher","first-page":"83392","DOI":"10.18632\/oncotarget.13110","volume":"7","author":"CB Schiller","year":"2016","unstructured":"Schiller, C. B. et al. CD19-specific triplebody SPM-1 engages NK and \u03b3\u03b4 T cells for rapid and efficient lysis of malignant B-lymphoid cells. Oncotarget 7, 83392\u201383408 https:\/\/doi.org\/10.18632\/oncotarget.13110 (2016).","journal-title":"Oncotarget"},{"key":"1534_CR93","unstructured":"Ding, L. et al. INB-619 \u2014 a novel gamma-delta (\u03b3\u03b4) T cell engager to target B cells in autoimmune diseases [abstract]. In ACR Convergence 2025 1535 (ACR, 2025)."},{"key":"1534_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103883","volume":"24","author":"T Wang","year":"2025","unstructured":"Wang, T. et al. The role of \u03b3\u03b4 T cells and CAR-\u03b3\u03b4 T cell therapy in autoimmune diseases. Autoimmun. Rev. 24, 103883 https:\/\/doi.org\/10.1016\/j.autrev.2025.103883 (2025).","journal-title":"Autoimmun. Rev."},{"key":"1534_CR95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/cdd.2013.26","volume":"21","author":"CJ Chan","year":"2014","unstructured":"Chan, C. J., Smyth, M. J. & Martinet, L. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ. 21, 5\u201314 https:\/\/doi.org\/10.1038\/cdd.2013.26 (2014).","journal-title":"Cell Death Differ."},{"key":"1534_CR96","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","volume":"24","author":"A Fenis","year":"2024","unstructured":"Fenis, A., Demaria, O., Gauthier, L., Vivier, E. & Narni-Mancinelli, E. New immune cell engagers for cancer immunotherapy. Nat. Rev. Immunol. 24, 471\u2013486 https:\/\/doi.org\/10.1038\/s41577-023-00982-7 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1534_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102500","volume":"13","author":"C Capuano","year":"2021","unstructured":"Capuano, C. et al. Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs. Cancers 13, 2500 https:\/\/doi.org\/10.3390\/cancers13102500 (2021).","journal-title":"Cancers"},{"key":"1534_CR98","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.apsb.2024.10.014","volume":"15","author":"LC Naatz","year":"2025","unstructured":"Naatz, L. C., Dong, S., Evavold, B., Ye, X. & Chen, M. Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: a new avenue for autoimmune disease treatment. Acta Pharm. Sin. B 15, 1230\u20131241 https:\/\/doi.org\/10.1016\/j.apsb.2024.10.014 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"1534_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100783","volume":"3","author":"O Demaria","year":"2022","unstructured":"Demaria, O. et al. Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell Rep. Med. 3, 100783 https:\/\/doi.org\/10.1016\/j.xcrm.2022.100783 (2022).","journal-title":"Cell Rep. Med."},{"key":"1534_CR100","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7, 311\u2013321 https:\/\/doi.org\/10.1080\/19420862.2015.1007813 (2015).","journal-title":"MAbs"},{"key":"1534_CR101","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1158\/2326-6066.CIR-18-0319","volume":"6","author":"KR VanDerMeid","year":"2018","unstructured":"VanDerMeid, K. R. et al. Cellular cytotoxicity of next-generation CD20 monoclonal antibodies. Cancer Immunol. Res. 6, 1150\u20131160 https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0319 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1534_CR102","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41375-022-01805-9","volume":"37","author":"J Yu","year":"2023","unstructured":"Yu, J. et al. IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRP\u03b1, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRP\u03b1 interaction and Fc\u0263R engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 37, 695\u2013698 https:\/\/doi.org\/10.1038\/s41375-022-01805-9 (2023).","journal-title":"Leukemia"},{"key":"1534_CR103","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","volume":"21","author":"C Rolin","year":"2024","unstructured":"Rolin, C., Zimmer, J. & Seguin-Devaux, C. Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases. Cell Mol. Immunol. 21, 643\u2013661 https:\/\/doi.org\/10.1038\/s41423-024-01176-4 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"1534_CR104","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1380142","volume":"7","author":"B Li","year":"2017","unstructured":"Li, B. et al. CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy. Oncoimmunology 7, e1380142 https:\/\/doi.org\/10.1080\/2162402X.2017.1380142 (2017).","journal-title":"Oncoimmunology"},{"key":"1534_CR105","doi-asserted-by":"publisher","first-page":"39356","DOI":"10.18632\/oncotarget.17000","volume":"8","author":"B Li","year":"2017","unstructured":"Li, B. et al. Simultaneous exposure to Fc\u03b3R and Fc\u03b1R on monocytes and macrophages enhances antitumor activity in vivo. Oncotarget 8, 39356\u201339366 https:\/\/doi.org\/10.18632\/oncotarget.17000 (2017).","journal-title":"Oncotarget"},{"key":"1534_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1059133","volume":"13","author":"S Chakravorty","year":"2022","unstructured":"Chakravorty, S., Afzali, B. & Kazemian, M. EBV-associated diseases: current therapeutics and emerging technologies. Front. Immunol. 13, 1059133 https:\/\/doi.org\/10.3389\/fimmu.2022.1059133 (2022).","journal-title":"Front. Immunol."},{"key":"1534_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114797","volume":"163","author":"H He","year":"2023","unstructured":"He, H. et al. Immunotherapy of Epstein\u2013Barr virus (EBV) infection and EBV-associated hematological diseases with gp350\/CD89-targeted bispecific antibody. Biomed. Pharmacother. 163, 114797 https:\/\/doi.org\/10.1016\/j.biopha.2023.114797 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1534_CR108","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein\u2013Barr virus associated with multiple sclerosis. Science 375, 296\u2013301 https:\/\/doi.org\/10.1126\/science.abj8222 (2022).","journal-title":"Science"},{"key":"1534_CR109","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ady0210","volume":"17","author":"S Younis","year":"2025","unstructured":"Younis, S. et al. Epstein\u2013Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus. Sci. Transl. Med. 17, eady0210 https:\/\/doi.org\/10.1126\/scitranslmed.ady0210 (2025). This article demonstrates that EBV may drive SLE by reprogramming nuclear antigen-reactive B cells into activated antigen-presenting cells that promote systemic autoimmunity.","journal-title":"Sci. Transl. Med."},{"key":"1534_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114071","volume":"204","author":"M Subklewe","year":"2024","unstructured":"Subklewe, M. et al. Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study. Eur. J. Cancer 204, 114071 https:\/\/doi.org\/10.1016\/j.ejca.2024.114071 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1534_CR111","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","volume":"32","author":"F M\u00fcller","year":"2026","unstructured":"M\u00fcller, F. et al. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial. Nat. Med. 32, 1142\u20131151 https:\/\/doi.org\/10.1038\/s41591-025-04185-6 (2026). This phase I\/IIa study demonstrates that CD19-directed CAR-T cell treatment was feasible, well tolerated and clinically effective in 24 patients across different SAIDs.","journal-title":"Nat. Med."},{"key":"1534_CR112","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200027","volume":"9","author":"V Von Niederh\u00e4usern","year":"2022","unstructured":"Von Niederh\u00e4usern, V. et al. B-cell reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 9, e200027 https:\/\/doi.org\/10.1212\/nxi.0000000000200027 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1534_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626616","volume":"12","author":"J Ma","year":"2021","unstructured":"Ma, J. et al. Bispecific antibodies: from research to clinical application. Front. Immunol. 12, 626616 https:\/\/doi.org\/10.3389\/fimmu.2021.626616 (2021).","journal-title":"Front. Immunol."},{"key":"1534_CR114","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41573-024-01051-x","volume":"23","author":"PJ Carter","year":"2024","unstructured":"Carter, P. J. & Quarmby, V. Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics. Nat. Rev. Drug Discov. 23, 898\u2013913 https:\/\/doi.org\/10.1038\/s41573-024-01051-x (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1534_CR115","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004225","volume":"10","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology. J. Immunother. Cancer 10, e004225 https:\/\/doi.org\/10.1136\/jitc-2021-004225 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1534_CR116","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","volume":"21","author":"EMJ Van Brummelen","year":"2016","unstructured":"Van Brummelen, E. M. J., Ros, W., Wolbink, G., Beijnen, J. H. & Schellens, J. H. M. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist 21, 1260\u20131268 https:\/\/doi.org\/10.1634\/theoncologist.2016-0061 (2016).","journal-title":"Oncologist"},{"key":"1534_CR117","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/rheumatology\/kez430","volume":"59","author":"A Combier","year":"2020","unstructured":"Combier, A. et al. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. Rheumatology 59, 1347\u20131354 https:\/\/doi.org\/10.1093\/rheumatology\/kez430 (2020).","journal-title":"Rheumatology"},{"key":"1534_CR118","doi-asserted-by":"publisher","first-page":"183","DOI":"10.55563\/clinexprheumatol\/ftira8","volume":"40","author":"I Oomen","year":"2022","unstructured":"Oomen, I. et al. Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases. Clin. Exp. Rheumatol. 40, 183\u2013190 https:\/\/doi.org\/10.55563\/clinexprheumatol\/ftira8 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1534_CR119","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.23098","volume":"6","author":"S Bitoun","year":"2023","unstructured":"Bitoun, S. et al. Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies. JAMA Netw. Open 6, e2323098 https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.23098 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1534_CR120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-4423","volume":"146","author":"H Balanta Murcia","year":"2025","unstructured":"Balanta Murcia, H., Ignatz-Hoover, J. & Agarwal, N. Cost-effectiveness of CAR-T cell therapy compared to bispecific T-cell engagers in relapsed\/refractory multiple myeloma: a retrospective study using a Markov model. Blood 146, 4423 https:\/\/doi.org\/10.1182\/blood-2025-4423 (2025).","journal-title":"Blood"},{"key":"1534_CR121","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1080\/14796694.2024.2354157","volume":"20","author":"M Lei","year":"2024","unstructured":"Lei, M. et al. Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed\/refractory diffuse large B-cell lymphoma: an institutional perspective. Future Oncol. 20, 2189\u20132201 https:\/\/doi.org\/10.1080\/14796694.2024.2354157 (2024).","journal-title":"Future Oncol."},{"key":"1534_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115319","volume":"26","author":"B Amoozgar","year":"2025","unstructured":"Amoozgar, B., Bangolo, A., Habibi, M., Cho, C. & Goy, A. From molecular precision to clinical practice: a comprehensive review of bispecific and trispecific antibodies in hematologic malignancies. Int. J. Mol. Sci. 26, 5319 https:\/\/doi.org\/10.3390\/ijms26115319 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1534_CR123","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","volume":"406","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian, H., Pui, C. H. & Jabbour, E. Acute lymphocytic leukaemia. Lancet 406, 950\u2013962 https:\/\/doi.org\/10.1016\/S0140-6736(25)00864-5 (2025).","journal-title":"Lancet"},{"key":"1534_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu, J., Fu, J., Zhang, M. & Liu, D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia. J. Hematol. Oncol. 8, 104 https:\/\/doi.org\/10.1186\/s13045-015-0195-4 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"1534_CR125","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 https:\/\/doi.org\/10.1056\/NEJMoa1609783 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR126","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli, G. et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J. Clin. Oncol. 35, 1795\u20131802 https:\/\/doi.org\/10.1200\/JCO.2016.69.3531 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR127","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown, P. A. et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 325, 833\u2013842 https:\/\/doi.org\/10.1001\/jama.2021.0669 (2021).","journal-title":"JAMA"},{"key":"1534_CR128","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli, F. et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 325, 843\u2013854 https:\/\/doi.org\/10.1001\/jama.2021.0987 (2021).","journal-title":"JAMA"},{"key":"1534_CR129","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget, N. et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131, 1522\u20131531 https:\/\/doi.org\/10.1182\/blood-2017-08-798322 (2018).","journal-title":"Blood"},{"key":"1534_CR130","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow, M. R. et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N. Engl. J. Med. 391, 320\u2013333 https:\/\/doi.org\/10.1056\/NEJMoa2312948 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR131","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","volume":"9","author":"E Jabbour","year":"2022","unstructured":"Jabbour, E. et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 9, e878\u2013e885 https:\/\/doi.org\/10.1016\/S2352-3026(22)00285-X (2022).","journal-title":"Lancet Haematol."},{"key":"1534_CR132","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta, S. et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N. Engl. J. Med. 392, 875\u2013891 https:\/\/doi.org\/10.1056\/NEJMoa2411680 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR133","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.21.01766","volume":"40","author":"AS Advani","year":"2022","unstructured":"Advani, A. S. et al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J. Clin. Oncol. 40, 1574\u20131582 https:\/\/doi.org\/10.1200\/JCO.21.01766 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01597-8","volume":"17","author":"J Lu","year":"2024","unstructured":"Lu, J. et al. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. J. Hematol. Oncol. 17, 79 https:\/\/doi.org\/10.1186\/s13045-024-01597-8 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1534_CR135","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Foa","year":"2024","unstructured":"Foa, R. et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J. Clin. Oncol. 42, 881\u2013885 https:\/\/doi.org\/10.1200\/JCO.23.01075 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR136","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa, R. et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N. Engl. J. Med. 383, 1613\u20131623 https:\/\/doi.org\/10.1056\/NEJMoa2016272 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01539-4","volume":"17","author":"T Shi","year":"2024","unstructured":"Shi, T. & Zhu, H. H. Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting. J. Hematol. Oncol. 17, 18 https:\/\/doi.org\/10.1186\/s13045-024-01539-4 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1534_CR138","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler, M. E. et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J. Clin. Oncol. 34, 1104\u20131111 https:\/\/doi.org\/10.1200\/JCO.2014.59.1586 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR139","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot, A. et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood 127, 1410\u20131416 https:\/\/doi.org\/10.1182\/blood-2015-06-651380 (2016).","journal-title":"Blood"},{"key":"1534_CR140","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","volume":"61","author":"L Coyle","year":"2020","unstructured":"Coyle, L. et al. Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk. Lymphoma 61, 2103\u20132112 https:\/\/doi.org\/10.1080\/10428194.2020.1759055 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"1534_CR141","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nbt.2621","volume":"31","author":"C Spiess","year":"2013","unstructured":"Spiess, C. et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat. Biotechnol. 31, 753\u2013758 https:\/\/doi.org\/10.1038\/nbt.2621 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1534_CR142","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn, L. H. et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood 145, 708\u2013719 https:\/\/doi.org\/10.1182\/blood.2024025454 (2025).","journal-title":"Blood"},{"key":"1534_CR143","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1200\/JCO-25-01957","volume":"43","author":"LE Budde","year":"2025","unstructured":"Budde, L. E. et al. Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase III SUNMO trial. J. Clin. Oncol. 43, 3799\u20133811 https:\/\/doi.org\/10.1200\/JCO-25-01957 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1534_CR144","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3324\/haematol.2024.285343","volume":"110","author":"AG Minson","year":"2025","unstructured":"Minson, A. G. & Dickinson, M. J. New bispecific antibodies in diffuse large B-cell lymphoma. Haematologica 110, 1483\u20131499 https:\/\/doi.org\/10.3324\/haematol.2024.285343 (2025).","journal-title":"Haematologica"},{"key":"1534_CR145","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220\u20132231 https:\/\/doi.org\/10.1056\/NEJMoa2206913 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1534_CR146","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont, C. et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38, 2653\u20132662 https:\/\/doi.org\/10.1038\/s41375-024-02410-8 (2024).","journal-title":"Leukemia"},{"key":"1534_CR147","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","volume":"6","author":"WS Kim","year":"2025","unstructured":"Kim, W. S. et al. Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat. Cancer 6, 528\u2013539 https:\/\/doi.org\/10.1038\/s43018-025-00921-6 (2025).","journal-title":"Nat. Cancer"},{"key":"1534_CR148","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010064","volume":"12","author":"X Liang","year":"2024","unstructured":"Liang, X. et al. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. J. Immunother. Cancer 12, e010064 https:\/\/doi.org\/10.1136\/jitc-2024-010064 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1534_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9","volume":"14","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero, P. et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 14, 24 https:\/\/doi.org\/10.1038\/s41408-023-00966-9 (2024).","journal-title":"Blood Cancer J."},{"key":"1534_CR150","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","volume":"11","author":"K Elkins","year":"2012","unstructured":"Elkins, K. et al. FcRL5 as a target of antibody\u2013drug conjugates for the treatment of multiple myeloma. Mol. Cancer Ther. 11, 2222\u20132232 https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0087 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"1534_CR151","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee, H. et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat. Med. 29, 2295\u20132306 https:\/\/doi.org\/10.1038\/s41591-023-02491-5 (2023).","journal-title":"Nat. Med."},{"key":"1534_CR152","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bjh.19455","volume":"205","author":"S Grigg","year":"2024","unstructured":"Grigg, S., Minson, A., Prins, E. & Dickinson, M. J. Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high. Br. J. Haematol. 205, 122\u2013126 https:\/\/doi.org\/10.1111\/bjh.19455 (2024).","journal-title":"Br. J. Haematol."},{"key":"1534_CR153","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13636","volume":"169","author":"Y Yao","year":"2023","unstructured":"Yao, Y., Hu, Y. & Wang, F. Trispecific antibodies for cancer immunotherapy. Immunology 169, 389\u2013399 https:\/\/doi.org\/10.1111\/imm.13636 (2023).","journal-title":"Immunology"},{"key":"1534_CR154","doi-asserted-by":"publisher","unstructured":"Falchi, L. et al. Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.07.02.24309792 (2024).","DOI":"10.1101\/2024.07.02.24309792"},{"key":"1534_CR155","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij, C. P. M. et al. Preclinical activity and determinants of response of the GPRC5D\u00d7CD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 5, 2196\u20132215 https:\/\/doi.org\/10.1182\/bloodadvances.2020003805 (2021).","journal-title":"Blood Adv."},{"key":"1534_CR156","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"A Baessler","year":"2024","unstructured":"Baessler, A. & Vignali, D. A. A. T cell exhaustion. Annu. Rev. Immunol. 42, 179\u2013206 https:\/\/doi.org\/10.1146\/annurev-immunol-090222-110914 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"1534_CR157","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","volume":"6","author":"AE Broske","year":"2022","unstructured":"Broske, A. E. et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma. Blood Adv. 6, 1025\u20131037 https:\/\/doi.org\/10.1182\/bloodadvances.2021005954 (2022).","journal-title":"Blood Adv."},{"key":"1534_CR158","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo4271","volume":"8","author":"PM Chen","year":"2022","unstructured":"Chen, P. M. et al. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci. Adv. 8, eabo4271 https:\/\/doi.org\/10.1126\/sciadv.abo4271 (2022).","journal-title":"Sci. Adv."},{"key":"1534_CR159","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.celrep.2019.12.014","volume":"30","author":"E Katsuyama","year":"2020","unstructured":"Katsuyama, E. et al. The CD38\/NAD\/SIRTUIN1\/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections. Cell Rep. 30, 112\u2013123.e4 https:\/\/doi.org\/10.1016\/j.celrep.2019.12.014 (2020).","journal-title":"Cell Rep."},{"key":"1534_CR160","doi-asserted-by":"publisher","first-page":"e195170","DOI":"10.1172\/jci.insight.195170","volume":"11","author":"NW Fluder","year":"2026","unstructured":"Fluder, N. W. et al. Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus. JCI Insight 11, e195170 https:\/\/doi.org\/10.1172\/jci.insight.195170 (2026).","journal-title":"JCI Insight"},{"key":"1534_CR161","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.trecan.2025.06.013","volume":"11","author":"JK Lue","year":"2025","unstructured":"Lue, J. K., Healton, S. E. & Salles, G. A. Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma. Trends Cancer 11, 1118\u20131129 https:\/\/doi.org\/10.1016\/j.trecan.2025.06.013 (2025).","journal-title":"Trends Cancer"},{"key":"1534_CR162","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","volume":"133","author":"E Curran","year":"2019","unstructured":"Curran, E. & Stock, W. Taking a \u201cBiTE out of ALL\u201d: blinatumomab approval for MRD-positive ALL. Blood 133, 1715\u20131719 https:\/\/doi.org\/10.1182\/blood-2018-12-852376 (2019).","journal-title":"Blood"},{"key":"1534_CR163","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich, B. et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann. Rheum. Dis. 83, 30\u201347 https:\/\/doi.org\/10.1136\/ard-2022-223764 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR164","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles, P. et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann. Rheum. Dis. 77, 1143\u20131149 https:\/\/doi.org\/10.1136\/annrheumdis-2017-212878 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1534_CR165","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00210-025-04425-z","volume":"399","author":"OA Sayed","year":"2026","unstructured":"Sayed, O. A., Ellebedy, M., Abu-Alsaud, M. A., Meligy, A. I. B. & Gheita, T. A. CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies. Naunyn Schmiedebergs Arch. Pharmacol. 399, 1565\u20131588 https:\/\/doi.org\/10.1007\/s00210-025-04425-z (2026).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"1534_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.07.016","author":"M Scherlinger","year":"2026","unstructured":"Scherlinger M., Avouac J. & Tsokos G. C. Immune reset after deep B-lineage depletion: remission is not reprogramming. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2026.07.016 (2026).","journal-title":"Ann Rheum Dis."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01534-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01534-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:58:25Z","timestamp":1791359905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01534-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":166,"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01534-z","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"24 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. is a consultant for Abbvie, Amgen, AstraZeneca, Biogen, BMS, Celltrion, Fresenius, GSK, Innate Pharma, Nordic Pharma and Novartis. G.C.T. is on the scientific advisory boards of CUGENE and CorEvitas. M.F.K. is a consultant for Alexion Pharmaceuticals, Allogene, Amgen, Argenx, Atara Biotherapeutics, Bristol Myers Squibb, Legend Biotech, Revel Pharmaceuticals, Sana Biotechnology, Sanofi, UCB\/Biogen, Umoja Biopharma\u00a0and Winnow Therapeutics. M.F.K. received research support from AstraZeneca, Blackbird Labs, NorthStar Medical Radioisotope\u00a0and Winnow Therapeutics. M.F.K. is a founder of and holds equity in Winnow Therapeutics. The Johns Hopkins University (JHU) has filed patent applications related to technologies described in this manuscript on which M.F.K. is listed as an inventor. The terms of these arrangements are being managed by JHU according to its conflict-of-interest policies.\u00a0The other authors declare no additional competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}